Top challenges and opportunities in clinical trials revealed in study
A study of clinical trial professionals has revealed the top challenges and frustrations with current Randomization and Trial Supply Management/Interactive Response Technology (RTSM/IRT) systems as well as opportunities for improvement.
The study, from Oracle Health Sciences in partnership with Informa Engage, showed that more than 70% of respondents found integration with other platforms; slowness to build, test and deploy new trials; and lack of flexibility and inability to support study changes to be the top three challenges they faced.
When looking at the reasons for delays in clinical trials in more detail, the study revealed that 92% of respondents had been required to make changes to their RTSM/IRT systems due to study changes, and on an average of two times per study.
Additionally, the survey highlighted that the most anticipated change in RTSM/IRT within the next five years is the integration of IRT into the eClinical platform, followed by accelerated trial builds, and completely self-service solutions, which reflects a desire for the top current challenges to be addressed in the next generation of RTSM/IRT platforms.
“When you’re developing software to help people with a specific business process, such as clinical research, it’s important to stay in tune with the market to ensure you’re always innovating to address their top challenges and delighting them with a solution that makes their job easier,” said Steve Rosenberg, general manager, Oracle Health Sciences. “The findings from this research confirm the pain points that we address with our new Clinical One Randomization and Supplies Management Cloud Service and that we are aligned with what the market wants in a modern RTSM/IRT solution.”
Data for this study was generated through an online survey completed by 254 professionals in clinical operations, trial management and related functional areas with direct involvement in both Clinical Trial Operations and RTMS/IRT solutions.